BRAF and metastatic melanoma: More recently, greater improvements have been noted in metastatic melanoma patients treated with combination targeted therapies, particularity so the combination of BRAF (Dabrafenib) and MEK (Trametinib) inhibitors (Flaherty et al., 2012a).